New platforms deflect the financial impact of cancer tests
January 18, 2024
Cancer screening is a critical component in the fight against this pervasive disease, and early detection is key to improving treatment outcomes. A standout innovation in this field is the Trucheck™ Intelli, a part of the Lifegen portfolio. This advanced cancer blood test screen marks a significant leap forward in the early detection of cancer, capable of identifying over 70 types of solid tumors from just a 25ml blood sample.
The Trucheck™ Intelli test’s importance in regular cancer screening is paramount, particularly because many cancers do not exhibit symptoms in their initial stages. The test’s exceptional sensitivity and precision make it a vital tool in cancer detection. It boasts a 99.9% sensitivity rate for positive results, detecting circulating tumor cells (CTCs) – key indicators absent in healthy individuals or those with benign conditions. This high accuracy is essential for distinguishing between cancer patients and healthy individuals.
Even when the test returns a negative result, indicating no CTCs, it still maintains an 88.2% sensitivity rate. This offers considerable peace of mind, though it’s crucial to understand that it doesn’t entirely eliminate the possibility of cancer. In cases of indeterminate results, where CTCs are detected but the specific cancer type or origin is unclear, a follow-up test is provided at no additional charge.
The process of undergoing the Trucheck™ Intelli test is designed to be patient-friendly and efficient. It involves an initial consultation, a pre-assessment, followed by the blood test at a scheduled appointment. The results are typically available within 18 days, followed by a comprehensive consultation to discuss the findings and the next steps.
Targeted at healthy adults aged 35 and above, Trucheck™ Intelli is a crucial addition to regular health check-ups for this demographic. While it is a powerful screening tool, it is important to use it in conjunction with other standard cancer screenings as recommended by healthcare professionals.
In summary, Trucheck™ Intelli, a part of the Lifegen portfolio, represents a significant advancement in cancer screening technology. Its ability to detect a wide array of cancers with high sensitivity and accuracy makes it an invaluable asset in the early detection and successful treatment of cancer. Integrating such innovative screening methods into annual health check-ups can greatly increase the chances of early detection, offering a better prognosis and potentially saving lives.
